荷蘭Agendia  www.agendia.com
Agendia是開發(fā)基于基因表達(dá)分析的診斷工具的全球領(lǐng)導(dǎo)企業(yè)。公司關(guān)注使用腫瘤基因表達(dá)分析的診斷化驗(yàn)工具的開發(fā)與商業(yè)化。Agendia率先對于預(yù)后檢驗(yàn)——MammaPrint®——進(jìn)行了商業(yè)化，從而能夠預(yù)測乳腺癌重發(fā)的機(jī)率。Agendia的產(chǎn)品線最近又新增了發(fā)現(xiàn)未知癌瘤的CupPrint®檢驗(yàn)。Agendia與荷蘭癌癥研究院(NKI)保持著密切聯(lián)系，從而能夠接觸到癌癥研究的最新發(fā)展。在開發(fā)出了新型癌癥診斷技術(shù)之后，Agendia將會發(fā)揮它的專家技術(shù)，為那些關(guān)注治癌新藥開發(fā)的企業(yè)尋找想要的新基因表達(dá)式。
荷蘭Agendia 
In 2008, Agendia launches its diagnostic test TargetPrint for breast cancer patients, which allows to obtain highly reliable quantitative data about each patients breast tumor and adds a secure prognostic tool for future treatment.

Leveraging the benefits of gene expression profiling 
- microarray technology – and collaboration
The leaders of Agendia are the inventors and initiators of diagnostic microarray testing - the technology which forms the basis for the company’s commercially available tests.
Clinically-relevant tumor gene expression profiles are established through in-house research, research collaborations and strategic alliances with leading academic institutes. In particular, Agendia has very close links, both geographically and collaboratively, with The Netherlands Cancer Institute.
Once validated, these profiles are used to develop commercially available tests utilizing the microarray technology. Tests are currently performed in a high quality clinical laboratory at the company’s headquarters in Amsterdam, The Netherlands.

A growing business
Agendia working to develop further tests and applications and to market the current test portfolio globally through direct sales and an expanding distribution network. Both MammaPrint and CupPrint* are CE-marked and the company is ISO 17025 and CLIA accredited.